1-3 of 3
Megan T Du
Close
Sort by
Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Seth J Welsh, Benjamin G Barwick, Erin Meermeier, Daniel Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E Sharik, Megan T Du, Victoria Marie Garbitt, Caleb K Stein, Joachim L Petit, Nathalie Meurice, Rodrigo Fonseca, Kennedi Todd, Sochilt Brown, Yuliza Tafoya Alvarado, Zachary Hammond, Nicklus Cuc, Courtney Wittenberg, Camille Herzog, Lawrence H. Boise, Nizar J. Bahlis, Paola Neri, W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel
Journal: Blood
Blood (2022) 140 (Supplement 1): 12997.
https://doi.org/10.1182/blood-2022-169920
Published: 2022
Journal Articles

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Francesco Maura, David Coffey, Esteban Braggio, Caleb K Stein, Meaghen E Sharik, Megan T Du, Bachisio Ziccheddu, Gareth J. Morgan, Ola Landgren, P. Leif Bergsagel, Marta Chesi
Journal: Blood
Blood (2022) 140 (Supplement 1): 1540–1541.
https://doi.org/10.1182/blood-2022-166614
Published: 2022
Journal Articles

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model

Erin Meermeier, Caleb K Stein, Meaghen E Sharik, Yuan Xiao Zhu, Megan T Du, Seth J Welsh, Chang-Xin Shi, Matthew L Wheeler, P. Leif Bergsagel, Marta Chesi
Journal: Blood
Blood (2022) 140 (Supplement 1): 7056–7057.
https://doi.org/10.1182/blood-2022-167668
Published: 2022